# InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Scales Manufacturing, Eyes Global Commercialization of AVERSA(TM)

Nutriband (NASDAQ: NTRB) was featured in a recent publication that discussed the company’s milestones, innovative platform, and lead product, AVERSA(TM) Fentanyl. NTRB’s technology “incorporates aversive agents into fentanyl patches to prevent misuse and accidental exposure. The company has built a global IP protection strategy, securing patents across the United States, Europe, Asia and Australia. With commercialization manufacturing scaled up in collaboration with Kindeva, Nutriband is poised for submission to the FDA, potentially initiating a transition that would unlock major revenue opportunities,” the article reads. The piece further highlights Nutriband’s vision in creating value for shareholders and laser focus on finalizing its development pathway to FDA approval.

 To view the full article, visit https://ibn.fm/CPNhF

 About Nutriband Inc.

 Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse deterrent fentanyl patch incorporating its AVERSA(TM) abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information about the company, visit www.Nutriband.com.

 NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

 About InvestorWire

 InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

 For more information, please visit https://www.InvestorWire.com

 Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

 InvestorWireAustin, Texaswww.InvestorWire.com512.354.7000 OfficeEditor@InvestorWire.com

 InvestorWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/iw/investornewsbreaks-nutriband-inc-nasdaq-ntrb-scales-manufacturing-eyes-global-commercialization-of-aversatm/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/nutriband-s-aversatm-fentanyl-patch-nears-fda-submission-to-combat-opioid-abuse/37d4e0250a94b2ba94cd2293975cf527) 

 



[Reddit Post](https://www.reddit.com/r/Business_NewsRamp/comments/1ncthsn/nutribands_aversa_fentanyl_patch_nears_fda/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/259/9/pear94d_.webp)